⚠ Evidence warning: Clinical trials or other evidence do not support the claims that the autoimmune and pregnancy cautions about Echinacea are myths, that short-term use is not contraindicated in stable autoimmune disease, and that severe reactions occur in only 1 per 100,000 to 1 per 1,000,000 user-exposures. This page keeps it as a report of what people, websites or other media say.

Echinacea Safety and Autoimmune Cautions

A mild skin rash, one type of allergic reaction reported
A mild skin rash, one type of allergic reaction reported
Spiny daisy-family pollen, the source of Asteraceae allergy
Spiny daisy-family pollen, the source of Asteraceae allergy
Testing echinacea products for identity and contamination
Testing echinacea products for identity and contamination

Echinacea has been widely consumed for more than 150 years by Native American, European, and North American populations, with one of the most thoroughly documented safety profiles in the herbal medicine literature. Despite this track record, two myths persist that have unnecessarily scared patients away from a useful herb — that Echinacea is contraindicated in autoimmune disease (the theoretical concern was never demonstrated clinically), and that Echinacea is unsafe in pregnancy (a 2000 prospective study by Gallo and colleagues at the Motherisk Program documented no teratogenicity). Two cautions are widely repeated — that Echinacea is contraindicated in autoimmune disease (the concern rests mainly on laboratory immune-stimulation findings; no clinical trial has documented worsening, though dermatologists have published case reports of flares after immune-stimulating herbs), and that Echinacea is unsafe in pregnancy (a 2000 prospective study by Gallo and colleagues at the Motherisk Program found no increase in major malformations). The genuine safety concerns are narrower and more specific: allergic reactions in patients sensitized to the Asteraceae (daisy) plant family (ragweed, chrysanthemum, marigold, dandelion, sunflower), occasional gastrointestinal upset particularly with high-dose tinctures, modest cytochrome P450 3A4 induction with potential to alter the metabolism of certain prescription drugs, and a pediatric labeling restriction in some jurisdictions for children under 12. This deep-dive sets out what the evidence shows for each concern and whom the research raises concerns for.


Table of Contents

  1. Overall Safety Profile
  2. The Autoimmune Contraindication Myth
  3. Why the Myth Persists
  4. Pregnancy and Lactation — The Gallo 2000 Study
  5. Asteraceae Family Allergy — The Genuine Concern
  6. Pediatric Use and Labeling Restrictions
  7. Drug Interactions (Cytochrome P450 3A4, CYP1A2)
  8. Gastrointestinal and Mucosal Side Effects
  9. Transplant Recipients and Active Immunosuppression
  10. Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome and Severe Immunodeficiency
  11. Contamination, Adulteration, and Quality
  12. Key Research Papers
  13. Connections
  14. Featured Videos

Overall Safety Profile

Echinacea has one of the most extensively documented safety profiles of any medicinal herb in modern use. The relevant data come from:

The herb is approved as a traditional herbal medicinal product across the European Union under the EMA HMPC framework. The Botanical Safety Handbook rates Echinacea purpurea aerial parts as Safety Class 1 (the safest category) when used appropriately, with the only general caution being possible allergic reaction in Asteraceae-sensitive individuals.

The remainder of this page addresses the specific safety concerns that come up most frequently in clinical practice and patient questions, with explicit attention to separating evidence-based concerns from unsupported folklore.

Back to Table of Contents

The Autoimmune Contraindication Myth

The most widely repeated — and most poorly supported — safety concern about Echinacea is that it is contraindicated in autoimmune disease. This warning appears on supplement bottles, in patient handouts, on integrative-medicine websites, and is repeated by some clinicians. The concern rests mainly on laboratory findings: no clinical trial has documented worsening of autoimmune disease, while a small number of published case reports describe flares after immune-stimulating herbs (described below).

The origin of the concern is several in-vitro studies from the 1980s and 1990s showing that isolated polysaccharide fractions from Echinacea purpurea increased macrophage tumor necrosis factor-alpha production, interleukin-1 (IL-1) production, and interleukin-6 (IL-6) production, with secondary push toward Th1 T-cell differentiation. Extrapolation from these in-vitro observations produced the theoretical argument: "Autoimmune diseases like rheumatoid arthritis, lupus, and multiple sclerosis are characterized by Th1-mediated immune attack on self-tissue. If Echinacea pushes T cells toward Th1, it should worsen autoimmune disease. Therefore Echinacea is contraindicated in autoimmune disease."

The argument has several major problems:

  1. It extrapolates from isolated-constituent in-vitro studies to whole-plant clinical effect — whole-plant Echinacea preparations contain alkylamides (which work through CB2 to suppress inflammation), caffeic acid derivatives (which have direct anti-inflammatory effects), and polysaccharides. The net immunological effect of the combined preparation is modulation, not unidirectional Th1 stimulation. See the Immune Modulation deep-dive page for full mechanism discussion.
  2. The Th1/Th2 framework is itself oversimplified for modern autoimmune disease — rheumatoid arthritis, lupus, and multiple sclerosis are increasingly understood as Th17-driven rather than purely Th1-driven, and the Treg/Th17 balance (which Echinacea alkylamides push toward Treg, not Th17) is the more relevant axis. Pure Th1 push, if it occurred, would not necessarily worsen these diseases.
  3. No clinical trial of Echinacea in any population has documented worsening of autoimmune disease — the 24 trials in the Karsch-Volk Cochrane review collectively enrolled more than 4,600 participants, and the dozens of additional trials beyond the Cochrane review add thousands more. Pharmacovigilance data from European post-marketing surveillance covering millions of patient-exposures show no consistent autoimmune flare signal. If Echinacea consistently worsened autoimmune disease, the signal would be visible by now.
  4. Direct evidence in autoimmune populations comes from case reports rather than trials — in 2004 the dermatologists Lee and Werth described 3 patients whose autoimmune disease began or flared after taking supplements with immune-stimulating effects. Echinacea and the alga Spirulina platensis were implicated in 2 patients’ flares of pemphigus vulgaris (a blistering autoimmune skin disease); the third patient developed dermatomyositis after an algae supplement. The authors concluded that immune-stimulating herbal supplements may worsen existing autoimmune disease, or set it off in people genetically predisposed to it, possibly through increased tumor necrosis factor-alpha production, and that more research is needed to clarify the mechanisms.
  5. The theoretical concern would predict similar problems with many common foods — mushrooms (beta-glucans, similar polysaccharide immunostimulation), herbs containing caffeic acid derivatives (rosemary, basil), and yeast-fermented foods all have some macrophage-activating activity in vitro. The pattern of singling out Echinacea while ignoring these other exposures is inconsistent.

A 2025 systematic scoping review by Weiner and colleagues screened 11,819 articles and included 469 studies of herbal supplements with immune-stimulating effects in laboratory, animal and human research. Echinacea was one of 15 herbs with the strongest evidence across all three kinds of study (the others included alfalfa, ashwagandha, astragalus, garlic, ginseng, reishi mushroom and spirulina). These herbs shared pro-inflammatory mechanisms, including toll-like receptor activation and increased production of the inflammatory messengers interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, interleukin-12 and interferon-gamma. The review was compiled to identify supplements that may trigger or worsen autoimmune skin diseases; it collected evidence of immune-stimulating effects rather than counting flares in patients.

Taken together, the evidence on short-term Echinacea use in stable autoimmune disease consists of mechanistic reasoning in both directions, general-population trials that did not report autoimmune worsening, and case reports of flares. The current best evidence is that short-term Echinacea use is not contraindicated in stable autoimmune disease. Long-term continuous use in active autoimmune disease has even less evidence, and in people on immunosuppressive medications the herb-drug interaction is a further concern (discussed below).

What the evidence means for people with autoimmune disease:

Back to Table of Contents

Why the Myth Persists

The autoimmune-contraindication concern about Echinacea is a useful case study in how unsupported safety warnings propagate through the herbal-medicine literature and become entrenched despite contrary evidence:

As a result, many people with autoimmune disease have been told to avoid the herb on the basis of theory alone. At the same time, the published case reports of flares after immune-stimulating herbs (above) show that the concern is not entirely without clinical observations. The corrective work of replacing unsupported caution with evidence-based individualized recommendation is slow and ongoing.

Back to Table of Contents

Pregnancy and Lactation — The Gallo 2000 Study

The second widely repeated caution about Echinacea is that it is unsafe in pregnancy. The one prospective controlled study did not find an increased risk of major malformations.

The pivotal study is Gallo and colleagues 2000, published in Archives of Internal Medicine. The investigators at the Motherisk Program at the Hospital for Sick Children in Toronto enrolled 206 women who had taken Echinacea during pregnancy (most commonly E. purpurea, 112 of them during the first trimester, for cold and upper respiratory symptoms) and compared them with 206 control women with similar illnesses who had taken medicines not known to cause birth defects, matched for maternal age, alcohol use and cigarette use. Outcomes assessed included:

The study was not large enough to detect rare adverse effects, and follow-up was limited, but it remains the largest prospective pregnancy-exposure study for Echinacea and is consistently reassuring. Subsequent case reports and small observational studies have not contradicted the Gallo findings.

The current best-evidence position from major teratology databases:

For lactation, Echinacea is similarly considered low-risk. The LactMed database (NIH/NLM) notes "the limited data available indicates that the components are unlikely to cause adverse effects in breastfed infants" and lists Echinacea as compatible with breastfeeding at typical doses. Some traditional herbal texts even recommend low-dose Echinacea during breastfeeding as immune support for both mother and infant.

What this evidence means for pregnancy and lactation:

Back to Table of Contents

Asteraceae Family Allergy — The Genuine Concern

The genuine and well-documented safety concern with Echinacea is allergic reaction in patients sensitized to other members of the Asteraceae (Compositae, daisy) plant family. The Asteraceae is a large family containing many widely-encountered species, several of which are common allergens:

Patients with documented allergy to any of these — particularly those with seasonal ragweed allergy or hay fever to chrysanthemum-family plants — have an increased risk of allergic reaction to Echinacea. The reaction spectrum includes:

Mullins and Heddle (2002) reviewed 51 reports to the Australian Adverse Drug Reactions Advisory Committee that implicated Echinacea. Of these, 26 suggested a possible allergic (immunoglobulin E-mediated) reaction: 4 anaphylaxis, 12 acute asthma and 10 hives or swelling (urticaria/angioedema). The 26 patients were aged 2 to 58 years, 78% were female and more than half were known to be atopic (prone to allergies); 4 were hospitalized. Four reacted after their first known exposure to Echinacea. The authors also examined 5 patients themselves: 2 had anaphylaxis and a third had an acute asthma attack 10 minutes after the first dose of Echinacea they had ever taken. The estimated background rate of severe Echinacea reactions is in the range of 1 per 100,000 to 1 per 1,000,000 user-exposures — rare but not zero.

The same paper explains why a first dose can cause a reaction: 20 of 100 atopic people who had never taken Echinacea already had a positive skin-prick test to it. The authors concluded that cross-reactivity between Echinacea and other environmental allergens can sensitize people before they ever take the herb, and that atopic people are overrepresented among those who react.

What these findings mean in practice:

  1. The research raises the greatest concern for people with known severe ragweed, chrysanthemum, marigold, or chamomile allergy
  2. Mild seasonal hay fever to Asteraceae pollen does not mean a reaction will occur, but the skin-test data show that sensitization can exist before any Echinacea is taken, so a reaction to a first dose is possible
  3. New oral itching, hives, throat tightness, or difficulty breathing after taking Echinacea are signs of an allergic reaction; throat tightness and difficulty breathing are signs of anaphylaxis, which hospitals treat as urgent
  4. People with a history of severe allergic reactions to any plant carry the highest allergy risk with any new herbal exposure, including Echinacea
  5. Topical Echinacea preparations carry the same allergic-risk profile as oral; patch testing on a small skin area is one way sensitization is checked

Back to Table of Contents

Pediatric Use and Labeling Restrictions

Echinacea has been used in children for more than a century with generally good safety. The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom issued a 2012 advisory recommending against the use of oral Echinacea products in children under 12 years of age, primarily due to:

The MHRA position has been widely adopted and Echinacea products in the UK and some other European markets carry an "Do not use in children under 12" label. The position is more cautious than that of most other regulatory bodies — the US, Germany, and Canada do not have an explicit under-12 contraindication, though pediatric efficacy evidence is acknowledged to be more limited than adult evidence.

The current best evidence for pediatric Echinacea use:

What the pediatric evidence adds up to:

Back to Table of Contents

Drug Interactions (Cytochrome P450 3A4, CYP1A2)

Echinacea has modest effects on hepatic cytochrome P450 drug-metabolizing enzymes that can affect the metabolism of certain prescription drugs:

The clinically relevant interactions to be aware of:

For most over-the-counter medications, common prescription drugs without narrow therapeutic windows, and short-term Echinacea use, the interaction concerns are minor. The research raises the most concern about Echinacea-drug interaction for people on transplant immunosuppression, human immunodeficiency virus antiretrovirals, warfarin, or active chemotherapy.

Back to Table of Contents

Gastrointestinal and Mucosal Side Effects

Mild side effects with oral Echinacea include:

These side effects are generally minor and do not require discontinuation in most users. The tincture preparation can cause more pronounced oral effects than the encapsulated dry herb, and the pressed juice preparation falls in between. For patients sensitive to alcoholic tinctures, alcohol-free glycerite forms and pressed juice preparations exist.

Back to Table of Contents

Transplant Recipients and Active Immunosuppression

Solid organ transplant recipients and patients on active immunosuppression for severe autoimmune disease, hematologic malignancy, or stem cell transplant are the populations where Echinacea is most clearly contraindicated. The reasoning is straightforward:

  1. Immunosuppression is therapeutically intentional — the entire point of cyclosporine, tacrolimus, mycophenolate, antithymocyte globulin, and similar agents is to suppress the immune system enough to prevent rejection. An immunomodulatory herb that increases immune activity, however modestly, works against the therapeutic intent.
  2. Cytochrome P450 3A4 drug-interaction risk is concentrated in this population — many of the immunosuppressants are narrow-therapeutic-window cytochrome P450 3A4 substrates. Even small Echinacea-mediated changes in metabolism could push drug levels into toxicity or sub-therapeutic ranges with potentially serious consequences.
  3. Infection risk is already elevated — transplant patients are at high risk for opportunistic infections. The marginal benefit Echinacea might provide is outweighed by the risk of unpredictable interaction with the complex polypharmacy these patients require.
  4. Closely balanced drug regimens — an immune-modulating herb added to a transplant drug regimen adds an unmeasured influence on both drug levels and immune activity, which is why self-prescribed immunomodulatory herbs are considered contraindicated in this group.

For these reasons, the concern applies to transplant recipients, to patients on biologic immunosuppressants (tumor necrosis factor (TNF) inhibitors, IL-17 inhibitors, JAK inhibitors), in patients receiving active cancer chemotherapy, and in patients with active hematologic malignancy.

Back to Table of Contents

Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome and Severe Immunodeficiency

Human immunodeficiency virus/acquired immunodeficiency syndrome (AIDS) and other severe immunodeficiency conditions warrant specific consideration:

Back to Table of Contents

Contamination, Adulteration, and Quality

The supplement industry has historically had quality control challenges, and Echinacea is no exception:

What is known about judging product quality:

  1. A “standardized” label on its own did not guarantee content: in the Gilroy study fewer than half of the standardized products met their own label’s standard, and labelled milligrams were only weakly related to the measured content
  2. For tinctures, the tongue-tingling sensation is a direct quality-indicator for alkylamide content. A tincture that does not produce significant tongue tingling within 30 seconds of oral contact has likely lost its alkylamide potency
  3. Some products carry the mark of third-party testing programs such as USP Verified or NSF Certified, which test products independently of the manufacturer
  4. Labels differ in whether they specify species and plant part (E. purpurea aerial parts pressed juice, E. angustifolia root, etc.) or just say generic "Echinacea"; species and plant part change the constituent profile
  5. Because alkylamides degrade with heat and storage time, products that have sat on warm shelves for years are the most likely to have lost potency

Back to Table of Contents

Key Research Papers

  1. Gallo M, Sarkar M, Au W, Pietrzak K, Comas B, Smith M, Jaeger TV, Einarson A, Koren G (2000). Pregnancy outcome following gestational exposure to echinacea: a prospective controlled study. Archives of Internal Medicine 160(20):3141-3143. — PubMed PMID: 11074744
  2. Mullins RJ, Heddle R (2002). Adverse reactions associated with echinacea: the Australian experience. Annals of Allergy, Asthma and Immunology 88(1):42-51. — PubMed PMID: 11814277
  3. Taylor JA, Weber W, Standish L, Quinn H, Goesling J, McGann M, Calabrese C (2003). Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA 290(21):2824-2830. — PubMed PMID: 14657066
  4. Gilroy CM, Steiner JF, Byers T, Shapiro H, Georgian W (2003). Echinacea and truth in labeling. Archives of Internal Medicine 163(6):699-704. — PubMed PMID: 12639203
  5. Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD (2004). The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clinical Pharmacology and Therapeutics 75(1):89-100. — PubMed PMID: 14749695
  6. Perri D, Dugoua JJ, Mills E, Koren G (2006). Safety and efficacy of echinacea (Echinacea angustifolia, E. purpurea and E. pallida) during pregnancy and lactation. Canadian Journal of Clinical Pharmacology 13(3):e262-e267. — PubMed
  7. Mengs U, Clare CB, Poiley JA (1991). Toxicity of Echinacea purpurea. Acute, subacute and genotoxicity studies. Arzneimittelforschung 41(10):1076-1081. — PubMed
  8. Block KI, Mead MN (2003). Immune system effects of echinacea, ginseng, and astragalus: a review. Integrative Cancer Therapies 2(3):247-267. — PubMed
  9. Awang DV, Kindack DG (1991). Echinacea. Canadian Pharmaceutical Journal 124:512-516. — PubMed
  10. Mrozikiewicz PM, Bogacz A, Karasiewicz M, Mikolajczak PL, Ozarowski M, Seremak-Mrozikiewicz A, Czerny B, Bobkiewicz-Kozlowska T, Grzeskowiak E (2010). The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine 17(10):830-833. — PubMed
  11. Freeman C, Spelman K (2008). A critical evaluation of drug interactions with Echinacea spp. Molecular Nutrition and Food Research 52(7):789-798. — PubMed
  12. Karsch-Völk M, Barrett B, Kiefer D, Bauer R, Ardjomand-Woelkart K, Linde K (2014). Echinacea for preventing and treating the common cold. Cochrane Database of Systematic Reviews 2014(2):CD000530. — PubMed PMID: 24554461
  13. Lee AN, Werth VP (2004). Activation of autoimmunity following use of immunostimulatory herbal supplements. Archives of Dermatology 140(6):723-727. — PubMed PMID: 15210464
  14. Weiner JD, Hill A, Shen C, On A, Werth VP (2025). Identifying immunostimulatory herbal supplements that may flare autoimmune skin diseases: a systematic scoping review. Lupus Science & Medicine 12(2):e001803. — PubMed PMID: 41475897

PubMed Topic Searches

  1. PubMed: Echinacea autoimmune contraindication
  2. PubMed: Echinacea pregnancy lactation safety
  3. PubMed: Echinacea Asteraceae allergic reaction
  4. PubMed: Echinacea CYP450 interactions
  5. PubMed: Echinacea pediatric safety

Back to Table of Contents

Connections

Back to Table of Contents